Results 201 to 210 of about 104,823 (289)

A meta-analysis on the effectiveness and safety of FOLFOX plus bevacizumab for colorectal cancer treatment. [PDF]

Front Oncol
Ma W, Song Z, Zhu Y.
europepmc   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, Volume 159, Issue 3, Page 699-708, 1 August 2026.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source

Paradoxical Pyogenic Granuloma Associated With Ramucirumab but Not Bevacizumab: A Case Suggesting Differential Effects of VEGF Receptor and Ligand Inhibition. [PDF]

Respirol Case Rep
Nigi A, Iwamoto K, Itani H, Kondou S.
europepmc   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151. [PDF]

J Gastrointest Oncol
Cisarovsky C, Chau I.
europepmc   +1 more source

Feasibility and Safety of High‐Dose Proton Re‐Irradiation in Recurrent Pediatric Central Nervous System Tumors: A Single‐Institution Retrospective Study

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Purpose Pediatric central nervous system (CNS) tumors often recur despite multimodality therapy. Although re‐irradiation (re‐RT) has historically been limited by concerns for severe late toxicities, modern techniques have renewed interest in this approach. Proton therapy provides dosimetric advantages that may enable curative re‐treatment with
Jin‐Ho Song, Jonathan Baron, Carlos Chavez Perez, Sidharth Ramesh, Jane Minturn, Kavita A. Desai, Amish C. Shah, Jean M. Belasco, Kristina A. Cole, Michael J. Fisher, Phillip B. Storm, Peter M. Madsen, Goldie Kurtz, Robert A. Lustig, Christine Hill‐Kayser, Michael J. LaRiviere   +15 more
wiley   +1 more source

Reduced Local Tumor Progression After Thermal Ablation During Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. [PDF]

Cancers (Basel)
Nakabori T, Mukai K, Miyanaga T, Takiyama H, Sekiya K, Kinomoto T, Masumoto T, Murata J, Urabe M, Kai Y, Takada R, Morishima T, Shigekawa M, Ohkawa K.   +13 more
europepmc   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 81-93, July 2026.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan. [PDF]

Laryngoscope Investig Otolaryngol
Hashimli R, Aliyeva A.
europepmc   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, Volume 159, Issue 1, Page 198-209, 1 July 2026.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source